Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000902664-25-000190
Filing Date
2025-01-13
Accepted
2025-01-13 16:05:12
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 7558
  Complete submission text file 0000902664-25-000190.txt   9302
Mailing Address 1001 10TH AVENUE SOUTH SUITE 216 NAPLES FL 34102
Business Address 1001 10TH AVENUE SOUTH SUITE 216 NAPLES FL 34102 239-384-9750
Pentwater Capital Management LP (Filed by) CIK: 0001425851 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE
Type: SCHEDULE 13D/A

Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Subject) CIK: 0001661460 (see all company filings)

EIN.: 472846548 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91606 | Film No.: 25526386
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)